Pharma

Brazil imports billions worth of medicines from India annually. Now, Health Minister Alexandre Padilha wants to fundamentally rewrite that relationship. Rather than merely purchasing finished generics and active pharmaceutical ingredients from Indian manufacturers, Brazil seeks strategic partnerships to establish local production facilities, transfer technology, and build genuine pharmaceutical manufacturing capacity within Brazilian borders. This dramatic […]

India controls just 2 percent of the $400 billion global nutraceutical market. Yet FSSAI officials project the sector will outpace pharmaceuticals by tenfold—a claim that would sound audacious were it not grounded in converging forces rarely seen simultaneously in a single industry. Post-pandemic health consciousness has permanently shifted consumer behaviour away from reactive medicine towards

Uttar Pradesh’s inaugural Pharma Conclave 1.0 at Lucknow’s Taj Mahal Hotel on February 3, 2026, assembled India’s pharmaceutical royalty—Sun Pharma‘s Dilip Shanghvi, Dr Reddy’s Satish Reddy, Zydus‘ Pankaj Patel, Mankind‘s Ramesh Juneja—for what amounts to a declaration of intent: India’s most populous state wants to become its pharmaceutical powerhouse, wresting leadership from established hubs through

President Donald Trump’s February 2, 2026, Truth Social announcement slashing US reciprocal tariffs on Indian goods from 50% to 18%—whilst simultaneously waiving the 25% penalty on India’s Russian oil purchases—delivered an immediate and dramatic reward to India’s pharmaceutical sector before most Indian markets had even opened for trading. Nifty Pharma surged 2.96% by 9:28 AM

Finance Minister Nirmala Sitharaman’s Union Budget 2026-27, unveiled on February 1, presents a curious paradox in India’s healthcare priorities: a bold ₹10,000 crore Biopharma Shakti scheme championing domestic biologics and biosimilars innovation alongside customs duty waivers on 17 cancer drugs and seven rare disease therapies that could slash monthly treatment costs from ₹70,000-₹95,000—yet an overall

Last October, India’s pharmaceutical exports to the United States plummeted 23.7 per cent in a single month as tariff uncertainties triggered panic across the sector. By November, exports had rebounded with 9.8 per cent growth. This whiplash recovery encapsulates India’s pharmaceutical sector resilience—the world’s third-largest by volume provisioning 20 per cent of global generics demand—which

Thirty years ago, India’s pharmaceutical industry faced extinction. The 1995 TRIPS agreement forced product patents on a sector built entirely on reverse-engineering, threatening to obliterate the cost advantages enabling affordable generic production. Today, that same sector exports $30.5 billion annually—a sixteen-fold increase since 2001—commands 20 per cent of global generics supply, and holds 48.7 per

Ninety days. That’s how much time a pharmaceutical manufacturer can now save bringing a generic drug or biosimilar to Indian patients. On 28th January 2026, the Union Health Ministry unveiled sweeping amendments to the New Drugs and Clinical Trials Rules 2019, abolishing test licence requirements and introducing simple online intimation for bioavailability and bioequivalence studies

A generic drug manufacturer in Gujarat can now access all 27 European Union markets without paying a single rupee in tariffs. A medical device producer in Maharashtra suddenly faces European competition arriving 15 per cent cheaper than before. Both outcomes stem from the same transformative agreement. The India-EU Free Trade Agreement, sealed on 27th January